AGP Picks
View all

Privigen market seen growing as immune disorder demand rises

Nov. 10, 2026
Privigen market seen growing as immune disorder demand rises
By AI, Created 00:00 UTC, Nov 10, 2026, AGP -

The Privigen market is expected to expand over the coming years as more patients are diagnosed with immune-related disorders and use of immunoglobulin therapies grows. The Business Research Company says North America led the market in 2025, while Asia-Pacific is likely to post the fastest growth in the forecast period.

Why it matters: - Rising diagnoses of immune disorders are increasing demand for Privigen, an intravenous immunoglobulin therapy used in conditions such as primary immunodeficiency, CIDP and ITP. - The broader market could benefit from more home-based infusion care, stronger plasma supply chains and wider access to plasma-derived therapies. - The trend matters because Privigen is used to help restore antibody levels and support immune defense in patients with compromised immune systems.

What happened: - The Business Research Company published a market outlook on Privigen on Nov. 10, 2026. - The report says the Privigen market is positioned for steady growth over the coming years. - The analysis points to North America as the leading region in 2025. - The report expects Asia-Pacific to be the fastest-growing region in the forecast period. - Download a free sample of the report. - View the full market report.

The details: - Privigen is a human plasma-derived intravenous immunoglobulin therapy. - The treatment is used for primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy and idiopathic thrombocytopenic purpura. - The report links recent market growth to wider plasma donation networks, better diagnosis of primary immunodeficiency disorders, greater access to plasma-derived therapies, stronger clinical guidelines for IVIg use and more hospital-based infusion services. - Looking ahead, the report expects demand to rise from long-term immunotherapy use, homecare infusion services, investments to secure plasma supplies, higher autoimmune disease prevalence and manufacturing efficiency gains in IVIg production. - The report highlights stronger demand for immunoglobulin therapies, more plasma collection infrastructure, more home IVIg administration, improved plasma fractionation technology and a sharper focus on chronic immune disorder management. - Rising prevalence of immunodeficiency disorders is one of the main growth drivers identified in the analysis. - The report cites data showing the 19 most common autoimmune diseases affected 3% to 9% of the UK population in 2022 and 10% in 2023, based on a May 2023 University of Oxford update. - The report says this larger patient base is increasing demand for Privigen. - Favorable government programs are also supporting the market by improving healthcare access, affordability and treatment availability. - The report points to UK National Institute for Health and Care Research funding for the NIHR BioResource project, which rose from $50.89 million in 2022 to $1,005.17 million in 2023, supporting research into rare diseases and immunodeficiencies. - Increasing healthcare spending is another factor behind market growth. - The UK Office for National Statistics reported in May 2024 that total healthcare spending rose 5.6% in nominal terms from 2022 to 2023, compared with 0.9% growth in 2022. - The same report said long-term health and social care spending increased 2.8% in real terms in 2022. - The report includes new 2026 features such as market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated tables and graphics.

Between the lines: - The report frames Privigen as part of a broader shift toward chronic immune disorder management, where treatment demand rises alongside better diagnosis and longer patient survival. - The emphasis on homecare infusion and plasma supply investment suggests the market is moving beyond hospital-only delivery models. - Government funding and higher health spending appear to be enabling factors, but the report also implies supply-side capacity remains a critical constraint.

What's next: - The market outlook points to continued gains from expanding plasma collection, broader immunoglobulin use and more home-based administration. - Asia-Pacific's expected growth suggests future expansion will be shaped by improving healthcare access and rising disease burden outside mature Western markets. - The report signals that manufacturing efficiency and plasma supply security will remain important competitive themes. - The Business Research Company says additional report materials are available through its sales and marketing contacts, including Saumya Sahay at marketing@tbrc.info.

The bottom line: - Privigen demand is set to grow as immune disorder prevalence rises and healthcare systems expand access to immunoglobulin therapy.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

UK Post Observer

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

UK Post Observer

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.